ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor

He, L-N; Fu, S.; Ma, H.; Chen, C.; Zhang, X.; Li, H.; Du, W.; Chen, T.; Jiang, Y.; Wang, Y.; Wang, Y.; Zhou, Y.; Lin, Z.; Yang, Y.; Huang, Y.; Zhao, H.; Fang, W.; Zhang, H.*; Zhang, L.*; Hong, S.*广东省人民医院; 广州中医药大学; 中山大学
ESMO Open2022-12DOI: 10.1016/j.esmoop.2022.100630
8阅读
引用收藏
分享

摘要

Background: Tumor growth rate (TGR), denoted as percentage change in tumor size per month, is a well-established indicator of tumor growth kinetics. The predictive value of early on-treatment TGR (EOT-TGR) for immunotherapy remains unclear. We sought to establish and validate the association of EOT-TGR with treatment outcomes in patients with advanced non-small-cell lung cancer (aNSCLC) undergoing anti-PD-1/PD-L1 (programmed cell death protein 1/programmed death-ligand 1) therapy. @@@ Patients and methods: This bicenter retrospective cohort study included a training cohort, a contemporaneously treated internal validation cohort, and an external validation cohort. Computed tomography images were retrieved to calculate EOT-TGR, denoted as tumor burden change per month during a period between baseline and the first imaging evaluation after immunotherapy. Kaplan-Meier methodology and Cox regression analysis were conducted for survival analyses. @@@ Results: In the pooled cohort (n = 172), 125 patients (72.7%) were males; median age at diagnosis was 58 (range 28-79) years. Based on the training cohort, we determined the optimal cut-off value for EOT-TGR as 10.4%/month. Higher EOT-TGR was significantly associated with inferior overall survival [OS; hazard ratio (HR) 2.93, 95% confidence interval (CI) 1.47-5.83; P = 0.002], worse progression-free survival (PFS; HR 2.44, 95% CI 1.46-4.08; P = 0.001), and lower objective response rate (3.3% versus 20.9%; P = 0.040) and durable clinical benefit rate (6.7% versus 41.9%; P 0.001). Results were reproducible in the two validation cohorts for OS and PFS. Among 43 patients who had a best response of progressive disease in the training cohort, those with high EOT-TGR had worse OS (HR 2.64; P = .041) and were more likely to progress due to target lesions at the first tumor evaluation (85.2% versus 0.0%; P <0.001). @@@ Conclusions: Higher EOT-TGR was associated with inferior OS and immunotherapeutic response in patients with aNSCLC undergoing anti-PD-1/PD-L1 therapy. This easy-to-calculate radiologic biomarker may help evaluate the abilities of immunotherapy to prolong survival and assist in tailoring patients' management.

学科与关键词

关键词
tumor growth ratenon-small-cell lung cancerimmunotherapybiomarkerprognosis
相关
加载中…
  • Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study
    Yang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231206282.
  • Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy
    Leung, Elaine Lai-Han*; Li, Run-Ze; Fan, Xing-Xing; Wang, Lily Yan; Wang, Yan; Jiang, Zebo; Huang, Jumin; Pan, Hu-Dan; Fan, Yue; Xu, Hongmei; Wang, Feng; Rui, Haopeng; Wong, Piu; Sumatoh, Hermi; Fehlings, Michael; Nardin, Alessandra; Gavine, Paul; Zhou, Longen; Cao, Yabing*; Liu, Liang*Nature Communications, 2023, 14(1).被引 1
  • Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study
    Liu, Shuai; Zhao, Liuyuan; Zhou, Guohua*Frontiers in Genetics, 2022, 13: 1016085.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
ESMO Open
发表日期
2022-12
卷期
第 7 卷, 第 6 期
DOI
10.1016/j.esmoop.2022.100630
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81972898, 8217102281]; Natural Science Foundation of Guangdong Province [2019A1515011090]; Outstanding Young Talents Program of Sun Yat-sen University Cancer Center [16zxyc04]

作者

  • H

    He, L-N (第一作者)

    sun yat sen univ

  • F

    Fu, S.

    sun yat sen univ

查看全部 20 位作者收起作者
  • M

    Ma, H.

    2 · guangdong prov hosp · guangzhou univ chinese med

  • C

    Chen, C.

    sun yat sen univ

  • Z

    Zhang, X.

    sun yat sen univ

  • L

    Li, H.

    sun yat sen univ

  • D

    Du, W.

    sun yat sen univ

  • C

    Chen, T.

  • J

    Jiang, Y.

  • W

    Wang, Y.

  • W

    Wang, Y.

  • Z

    Zhou, Y.

  • L

    Lin, Z.

  • Y

    Yang, Y.

    sun yat sen univ

  • H

    Huang, Y.

    sun yat sen univ

  • Z

    Zhao, H.

  • F

    Fang, W.

    sun yat sen univ

  • Z

    Zhang, H. (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, L. (通讯)

    sun yat sen univ

  • H

    Hong, S. (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417